HMGN (Hemagen Diagnostics) Days Payable: 71.04 (As of Sep. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemagen Diagnostics Days Payable?

Hemagen Diagnostics HMGN Days Payable is 71.04 as of Sep. 2012.

Hemagen Diagnostics's average Accounts Payable for the three months ended in Sep. 2012 was $0.37 Mil. Hemagen Diagnostics's Cost of Goods Sold for the three months ended in Sep. 2012 was $0.47 Mil. Hence, Hemagen Diagnostics's Days Payable for the three months ended in Sep. 2012 was 71.04.

The historical rank and industry rank for Hemagen Diagnostics's Days Payable or its related term are showing as below:

HMGN's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.165
* Ranked among companies with meaningful Days Payable only.

Hemagen Diagnostics's Days Payable increased from Sep. 2011 (55.85) to Sep. 2012 (71.04). It may suggest that Hemagen Diagnostics delayed paying its suppliers.

Hemagen Diagnostics Days Payable Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics Days Payable Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.54 70.67 55.37 41.55 58.90

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.85 54.10 0.00 0.00 71.04

HMGN vs OBMP, NSPX, ATRX: Days Payable Comparison

For the Biotechnology subindustry, Hemagen Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemagen Diagnostics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Days Payable distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Days Payable falls into.


Hemagen Diagnostics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Hemagen Diagnostics's Days Payable for the fiscal year that ended in Sep. 2012 is calculated as

Days Payable (A: Sep. 2012 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Sep. 2011 ) + Accounts Payable (A: Sep. 2012 )) / count ) / Cost of Goods Sold (A: Sep. 2012 )*Days in Period
=( (0.415 + 0.369) / 2 ) / 2.429*365
=0.392 / 2.429*365
=58.90

Hemagen Diagnostics's Days Payable for the quarter that ended in Sep. 2012 is calculated as:

Days Payable (Q: Sep. 2012 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2012 ) + Accounts Payable (Q: Sep. 2012 )) / count ) / Cost of Goods Sold (Q: Sep. 2012 )*Days in Period
=( (0 + 0.369) / 1 ) / 0.474*365 / 4
=0.369 / 0.474*365 / 4
=71.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 71.04 mean?
Hemagen Diagnostics (HMGN) has a Days Payable of 71.04 as of Sep. 2012. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Days Payable too high?
Hemagen Diagnostics' current Days Payable is 71.04. The Biotechnology industry median Days Payable is 111.17. Hemagen Diagnostics' value of 71.04 is 36.1% below this industry median.
How does Hemagen Diagnostics' Days Payable compare to OBMP and NSPX?
Hemagen Diagnostics' Days Payable of 71.04 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 111.17. Hemagen Diagnostics' value of 71.04 is 36.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemagen Diagnostics's current Days Payable of 71.04 is 36.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hemagen Diagnostics and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemagen Diagnostics's current Days Payable is 71.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Days Payable of 71.04. The current Days Payable is 71.04 and 36.1% below the Biotechnology industry median of 111.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Days Payable is 71.04 as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.